PY2193067A - Compuestos moduladores del cftr, composiciones y usos de estos - Google Patents

Compuestos moduladores del cftr, composiciones y usos de estos

Info

Publication number
PY2193067A
PY2193067A PY202102193067A PY2193067A PY2193067A PY 2193067 A PY2193067 A PY 2193067A PY 202102193067 A PY202102193067 A PY 202102193067A PY 2193067 A PY2193067 A PY 2193067A PY 2193067 A PY2193067 A PY 2193067A
Authority
PY
Paraguay
Prior art keywords
compounds
compositions
methods
cftr
pde4
Prior art date
Application number
PY202102193067A
Other languages
English (en)
Inventor
Kyung Mi An
Ilji Jeong
Yearin Jun
Gunhee Kim
Jungho Kim
Kyeong-A Kim
Jinsun Kwon
Jin Hee Lee
Jooyun Lee
Jung Woo Lee
Myongjae Lee
Seolhee Lee
Dami Lim
Changmok Oh
Joontae Park
Jaeeun Ryu
Te-Ik Sohn
Hongchul Yoon
Jongmin Yoon
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of PY2193067A publication Critical patent/PY2193067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan compuestos moduladores de CFTR y composiciones que incluyen dichos compuestos. La presente divulgación también proporciona compuestos inhibidores de PDE4 y composiciones que incluyen dichos compuestos. También se proporcionan métodos para utilizar dichos compuestos y composiciones para modular CFTR, métodos para tratar una enfermedad o trastorno ocular y métodos para tratar indicaciones relacionadas con CFTR. La presente divulgación también proporciona métodos para utilizar dichos compuestos y composiciones para inhibir la PDE4, para tratar una enfermedad o trastorno inflamatorio y para tratar otras indicaciones relacionadas con la PDE4. También se proporcionan métodos de preparación de dichos compuestos y composiciones, y precursores sintéticos de dichos compuestos.
PY202102193067A 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos PY2193067A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063104979P 2020-10-23 2020-10-23

Publications (1)

Publication Number Publication Date
PY2193067A true PY2193067A (es) 2022-06-20

Family

ID=81290147

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202102193067A PY2193067A (es) 2020-10-23 2021-10-22 Compuestos moduladores del cftr, composiciones y usos de estos

Country Status (16)

Country Link
US (2) US11827640B2 (es)
EP (1) EP4232451A4 (es)
JP (1) JP2023547389A (es)
KR (1) KR20230096026A (es)
CN (1) CN116348468A (es)
AR (1) AR123884A1 (es)
AU (1) AU2021363703A1 (es)
CA (1) CA3196061A1 (es)
CL (1) CL2023001139A1 (es)
CO (1) CO2023006647A2 (es)
IL (1) IL302247A (es)
MX (1) MX2023004712A (es)
PY (1) PY2193067A (es)
TW (1) TW202233620A (es)
UY (1) UY39482A (es)
WO (1) WO2022084741A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114380835B (zh) * 2022-01-06 2022-12-27 南京桦冠生物技术有限公司 一种7-(3,4-二甲氧苯基)-2-吡唑[1,5-a]嘧啶羧酸的制备方法
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含ｃｆｔｒ調節劑化合物之點眼用組成物
CN120097921A (zh) * 2024-07-05 2025-06-06 广东省科学院动物研究所 二氟甲氧基苯基类pde4抑制剂及其应用
CN121609673A (zh) * 2026-02-02 2026-03-06 五邑大学 一种pde4抑制剂及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178449A (en) 1978-04-17 1979-12-11 American Cyanamid Company Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines
US4281000A (en) 1979-07-09 1981-07-28 American Cyanamid Company Substituted pyrazolo (1,5-a)pyrimidines and their use as anxiolytic agents
KR100191774B1 (ko) 1991-04-22 1999-06-15 오스카 아끼히꼬 피라졸로[1,5-알파] 피리미딘 유도체 및 이것을 함유하는 항염증제
WO2003037900A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US7196111B2 (en) 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
JP2004170323A (ja) 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
JP2006522750A (ja) * 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
WO2005037837A1 (ja) 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途
DE602004025747D1 (de) 2004-01-14 2010-04-08 Mallinckrodt Inc Zweiphasiges verfahren zur synthese ausgewählter pyrazolopyrimidine
JP2008508337A (ja) 2004-08-02 2008-03-21 シュバルツ ファルマ アクチェンゲゼルシャフト インドリジンカルボキサミド並びにそのアザ及びジアザ誘導体
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
AU2006305104B2 (en) 2005-10-21 2009-10-22 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-a]pyrimidine compounds as cannabinoid receptor antagonists
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
US20090275586A1 (en) 2006-10-06 2009-11-05 Kalypsys, Inc. Heterocyclic inhibitors of pde4
WO2008056176A1 (en) * 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
US20100331297A1 (en) * 2007-11-07 2010-12-30 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP5637859B2 (ja) * 2007-12-13 2014-12-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
WO2010063487A1 (en) * 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP5578490B2 (ja) 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
US8883789B2 (en) * 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US9029360B2 (en) 2012-03-29 2015-05-12 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines as metabotropic glutamate 5 receptor antagonists
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN103923105B (zh) 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
WO2016012896A1 (en) * 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
RU2742934C2 (ru) 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
CN107286156A (zh) 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018145080A1 (en) 2017-02-06 2018-08-09 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors

Also Published As

Publication number Publication date
EP4232451A4 (en) 2024-11-06
US20230080486A1 (en) 2023-03-16
TW202233620A (zh) 2022-09-01
CL2023001139A1 (es) 2023-11-17
CA3196061A1 (en) 2022-04-28
AU2021363703A1 (en) 2023-06-22
AU2021363703A9 (en) 2025-01-09
KR20230096026A (ko) 2023-06-29
UY39482A (es) 2022-05-31
MX2023004712A (es) 2023-05-09
WO2022084741A1 (en) 2022-04-28
AR123884A1 (es) 2023-01-18
CO2023006647A2 (es) 2023-05-29
EP4232451A1 (en) 2023-08-30
IL302247A (en) 2023-06-01
CN116348468A (zh) 2023-06-27
JP2023547389A (ja) 2023-11-10
US20240199623A1 (en) 2024-06-20
US11827640B2 (en) 2023-11-28

Similar Documents

Publication Publication Date Title
PY2193067A (es) Compuestos moduladores del cftr, composiciones y usos de estos
EA202091777A1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
DOP2021000222A (es) Moduladores de la vía integrada del estrés
CO2020005459A2 (es) Compuestos bicíclicos en puente como moduladores del receptor farnesoide x
CO2021008018A2 (es) Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
CL2020001931A1 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas.
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX2023001236A (es) Inhibidores de cinasa inducibles por sal.
CO2021010611A2 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
NI202000085A (es) Moduladores de la expresión de apol1
CO2020005486A2 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x
CO2023010940A2 (es) Compuestos moduladores de gcn2 y usos de los mismos
CL2024001566A1 (es) Moduladores de la vía integrada del estrés
CO2024004970A2 (es) Agentes degradantes de tyk2 y sus usos
GEAP202516670A (en) Tricyclic triazolo compounds as dgk inhibitors
WO2020021480A3 (en) Compositions and methods for treating the eye
MX2020009147A (es) Moduladores de la expresion de irf4.
MX2022012366A (es) Metodos para generar neuronas de dopamina del mesencefalo, neuronas del mesencefalo, y usos de las mismas.
CO2025008531A2 (es) Inhibidores de malt1
MX2017007114A (es) Una triazolopiridazina como un modulador de cinasa.
AR131101A1 (es) Heteroarilfluoroalquenos como inhibidores de dgk
MX2025012353A (es) Moduladores de cd38 y usos de los mismos
MX2023003035A (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de celulas falciforme.
CL2024000634A1 (es) Compuestos y métodos para modular splicing